Kymera completes Phase 2b enrollment 6 months early, accelerates KT-621 data to year-end 2026

Filed June 25, 2026 · Period ending June 25, 2026 · ~1 min read

Key Changes

• high

  Completed enrollment in BROADEN2 Phase 2b trial of KT-621 for moderate to severe atopic dermatitis approximately 6 months ahead of schedule, moving topline data readout from mid-2027 to year-end 2026.

  Item 8.01 — Other Events verify on EDGAR →
• high

  Plans to initiate Phase 3 trials in atopic dermatitis by mid-2027, subject to regulatory discussions, representing an accelerated development timeline enabled by early Phase 2b completion.

  Item 8.01 — Other Events verify on EDGAR →
• medium

  BROADEN2 trial evaluates three doses of KT-621 in approximately 200 patients aged 12-75 over 16 weeks, with primary endpoint measuring percent change in EASI score at Week 16.

  Exhibit 99.1 verify on EDGAR →